Susan Hall is Global Head of R&D at Valeant Pharmaceuticals International, Inc. (VRX). They have made 2 open-market trades across 2 companies since 2012, most recently 2016-03-11.
CIK 0001542052
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $55K since 2015, against 1 sale. Too few scored purchases to measure a record yet.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.